MRKNYSEChecked

What is Merck tied to?

Merck, known as MSD outside the US and Canada, makes the cancer drug Keytruda, the Gardasil vaccine and animal medicines. Keytruda brought in $8.6 billion of its $18.1 billion of sales in the third quarter of 2026, and its main US patents begin to expire in 2028.

Biggest ties: Alteogen (enzyme for Keytruda Qlex); Moderna (cancer treatment partner); Cancer patients (Keytruda and other cancer drugs)

The map

Suppliers sit above Merck, customers below. Tap a box, or step through with the arrows.

Merck depends on1 of 10

Alteogen

Size$830 million of Qlex sales (Q3 2026)

Keytruda Qlex, the version given as a shot under the skin, combines Keytruda with an enzyme licensed from Alteogen, a South Korean company. Qlex sold $830 million in the third quarter of 2026.

What to watch: How many patients move to Qlex before 2028.

Boxes with a corner arrow have their own map. Sizes show where a source gives one.

Outside forces

Things Merck can't control that affect its business. Tap one to see what to watch.

Keytruda patentsKeytruda and Qlex brought in about $31.7 billion in 2025, nearly half of Merck's sales. Key US patents on its active ingredient begin to expire in 2028, and Merck expects copies to affect sales materially from 2028 to 2029.What to watch

How much of Keytruda use moves to Qlex.

Sources: Labiotech: Merck and the Keytruda patent cliff; BioSpace: Merck wins subcutaneous approval for KeytrudaChecked

Buying new drugsMerck's 2026 outlook includes one-time charges of $6.05 a share for deals, mostly Cidara and Terns. It also bought Verona Pharma for about $10 billion in 2025, adding the lung drug Ohtuvayre, which sold $184 million in the third quarter.What to watch

Sales from the newer drugs.

Sources: Merck: third-quarter 2026 results (SEC); Merck: completes acquisition of Verona Pharma; Investing.com: Merck completes $10 billion Verona dealChecked

Newer medicinesWinrevair nearly doubled to $694 million in the third quarter of 2026.What to watch

Whether newer drugs can fill the Keytruda gap.

Sources: Merck: third-quarter 2026 results (SEC); Grafa: Merck Q3 2026 revenue rises 5%Checked

Latest earnings

Q3 2026, quarter to Sep 30, 2026

Reported Oct 29, 2026Next report date not announced yet

Revenue

$18.09B

Up 5% from $17.28B a year earlier

Earnings per share

$2.04

Down 12% from $2.32 a year earlier

Includes a one-time charge of $0.12 a share for a license deal with SciBrunch.

Sales, last four quartersIn billions of dollars. The last bar is the quarter above.
  1. $16.40BOct–Dec
    2025
  2. $16.29BJan–Mar
    2026
  3. $16.61BApr–Jun
    2026
  4. $18.09BJul–Sep
    2026

Source: Stock Analysis: MRK quarterly income statementChecked

Company outlook: Merck expects 2026 sales of $66.8 billion to $67.3 billion.

Ties to the map: Keytruda sold to the cancer patients on the map grew 6%, and Gardasil vaccine sales recovered.

Compared with the same quarter a year earlier, as reported by the company.

Sources: Merck: third-quarter 2026 results (SEC); Merck: Q3 2026 earnings infographic

Where the money comes from

Share of Merck's sales by business. Third quarter of 2026, as reported by the company.

By business

  • Keytruda48%$8.60B
  • Gardasil11%$2.00B
  • Other medicines31%$5.67B
  • Animal Health9%$1.68B
  • Other1%$0.14B

Merck's quarterly release does not split sales between the US and other countries.

Source: Merck: third-quarter 2026 results (SEC)Checked

Competes with

Bristol Myers SquibbCancer drugs
AstraZenecaCancer drugs
PfizerVaccines and cancer drugs

More in Drugmakers

Common questions

When does Keytruda lose patent protection?

Key US patents begin to expire in 2028. Merck expects copies to affect sales materially in 2028 to 2029.

What is Keytruda Qlex?

A version of Keytruda given as a quick shot under the skin instead of a drip. It uses an enzyme licensed from Alteogen and sold $830 million in the third quarter of 2026.

Why is Merck called MSD?

Merck & Co. uses the name MSD outside the US and Canada.

Read every connection

All 10 connections as cards, with sources. It's the same detail you get by tapping a box on the map.
Show allHide

Suppliers

The companies Merck relies on to make what it sells, with sources.

Alteogen

Enzyme for Keytruda Qlex

Size$830 million of Qlex sales (Q3 2026)

Keytruda Qlex, the version given as a shot under the skin, combines Keytruda with an enzyme licensed from Alteogen, a South Korean company. Qlex sold $830 million in the third quarter of 2026.

What to watch: How many patients move to Qlex before 2028.

Sources: I-MAK: Keytruda Qlex; Merck: third-quarter 2026 results summary (last10k)Checked

Daiichi Sankyo

Cancer drug partner

Size not disclosed in our sources

Merck works with Daiichi Sankyo on I-DXd, a cancer drug in development. An application for one type of lung cancer was voluntarily withdrawn in 2026.

What to watch: New filings for I-DXd.

Source: Merck: third-quarter 2026 results (SEC)Checked

Customers

Who buys from Merck or pays it, with sources.

Eisai

Lenvima partner

Size$287 million (Q3 2026)

Merck and Eisai share the drug Lenvima. Merck's alliance revenue from it was $287 million in the third quarter of 2026, up from $258 million.

What to watch: Lenvima alliance revenue.

Source: Merck: third-quarter 2026 results (SEC)Checked

Bayer

Adempas and Verquvo partner

Size$118 million (Q3 2026)

Merck and Bayer share the drugs Adempas and Verquvo. Merck's alliance revenue was $118 million in the third quarter of 2026.

What to watch: Alliance revenue each quarter.

Source: Merck: third-quarter 2026 results (SEC)Checked

Animal medicine buyers

Animal Health

Size$1.68 billion (Q3 2026)

Animal Health sales rose 4% to $1.68 billion in the third quarter of 2026.

What to watch: Animal Health growth each quarter.

Source: Merck: third-quarter 2026 results (SEC)Checked

About this page

Connections were last checked against company filings and news reports on Nov 21, 2026. Companies don't have to disclose every supplier or customer, so this map shows the most important ones that are publicly known, not every link.

How we check connections. StockTies is for information only. It is not investment advice. Spot something out of date? Tell us.